Please assess the completion status of the following clinical trial:

Trial Title: Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Life expectancy of at least 3 months~* Histologically- or cytologically-confirmed diagnosis of NSCLC that is anti-programmed cell death ligand 1 (PD-L1) positive per central laboratory review~* At least one bi-dimensional measurable lesion~* Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~Exclusion Criteria:~* Prior therapy with docetaxel for NSCLC~* Receiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive medication~* Currently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first dose~* Expected to require any other form of systemic or localized antineoplastic therapy while on trial~* History of allogeneic tissue/solid organ transplant~* Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of \>30 Gy within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug~* Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial~* Known history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, and has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents~* Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment~* Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after last dose of pembrolizumab or 180 days after last dose of docetaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab 2 mg/kg (Type: EXPERIMENTAL): Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
- Pembrolizumab 10 mg/kg (Type: EXPERIMENTAL): Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
- Docetaxel 75 mg/m^2 (Type: ACTIVE_COMPARATOR): Participants received docetaxel 75 mg/m\^2 IV over 1 hour Q3W for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).